Jiaci

Omalizumab Response Profile and Management

J Investig Allergol Clin Immunol 2019; Vol. 29(5): 338-348

doi: 10.18176/jiaci.0323

346

and Astellas. He has also received grant support for research

from Astellas.

Joaquín Sastre reports having served as a consultant to

Thermo Fisher, MSD, Novartis, Gennetech, Sanofi, Leti,

Roche, FAES FARMA, Mundipharma, and GSK and having

been paid lecture fees by Novartis, GSK, Stallergenes, LETI,

and FAES FARMA. He has also received grant support for

research from Thermo Fisher.

JF Silvestre has attended meetings organized by Sanofi,

Novartis, Menarini, Almirall, and Galderma. He has also

been invited to speak at meetings organized by Sanofi, MSD,

Novartis, and Janssen. He participates in advisory boards for

Novartis, Sanofi, and Viñas.

Marta Ferrer has served on advisory boards for Genentech

and has received a research grant and advisory and speaker

fees from Novartis. She has also received speaker fees from

FAES, MSD, and Menarini.

References

1. Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the

treatment of chronic spontaneous urticaria. Drug Des Devel

Ther. 2015;9:4.909-15.

2. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D,

Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO

Guideline for the Definition, Classification, Diagnosis and

Management of Urticaria. The 2017 Revision and Update.

Allergy. 2018.

3. MaurerM,Rosén K,HsiehHJ,Saini S,Grattan C,Gimenéz-Arnau

A, et al. Omalizumab for the treatment of chronic idiopathic or

spontaneous urticaria. N Engl J Med. 2013;368:924-35.

4. Beltrani VS. An overview of chronic urticaria. Clin Rev Allergy

Immunol. 2002;23:147-69.

5. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh

F, et al. The diagnosis and management of acute and

chronic urticaria: 2014 update. J Allergy Clin Immunol.

2014;133:1.270-7.

6. Lapi F, Cassano N, Pegoraro V, Cataldo N, Heiman F, Cricelli I, et

al. Epidemiology of chronic spontaneous urticaria: results from

a nationwide, population-based study in Italy. Br J Dermatol.

2016;174:996-1004.

7. Yosipovitch G, Greaves M. Chronic idiopathic urticaria: a

"Cinderella" disease with a negative impact on QoL and

health care costs. Arch Dermatol. 2008;144:102-3.

8. Ferrer M. Epidemiology, healthcare, resources, use and clinical

features of different types of urticaria. Alergológica 2005. J

Invest Allergol Clin Immunol. 2009;19 Suppl 2:21-6.

9. Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude

Elberink H, Giménez-Arnau A, et al. The Burden of Chronic

Spontaneous Urticaria Is Substantial: Real-World Evidence

From ASSURE-CSU. Allergy. 2017;72:2005-16.

10. Ferrer M, Bartra J, Giménez Arnau A, Jauregui I, Labrador-

Horrillo M, Ortiz de Frutos J, et al. Management of urticaria:

not too complicated, not too simple. Clin Exp Allergy.

2015;45:731-43.

11. Weller K, Maurer M, Grattan C, Nakonechna A, Abuzakouk

M, Bérard F, et al. ASSURE-CSU: a real-world study of burden

of disease in patients with symptomatic chronic spontaneous

urticaria. Clin Transl Allergy. 2015;5:29.

12. Curto-Barredo L, Riba Archilla L, Roura Vives G, Pujol RM,

Giménez-Arnau AM. Clinical Features of Chronic Spontaneous

Urticaria that Predict Disease Prognosis and Refractoriness to

Standard Treatment. Acta Derm Venereol. 2018;98:641-7.

13. Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso

E, Guillén-Grima F, Ferrer M. Updosing nonsedating

antihistamines in patients with chronic spontaneous urticaria:

a systematic review and meta-analysis. Br J Dermatol.

2016;175:1153-65.

14. Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan

E, Bradley MS, et al. Efficacy and safety of omalizumab in

patients with chronic idiopathic/spontaneous urticaria who

remain symptomatic on H1 antihistamines: a randomized,

placebo-controlled study. J Invest Dermatol. 2015;135:67-75.

15. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner

E, et al. Omalizumab in patients with symptomatic

chronic idiopathic/spontaneous urticaria despite standard

combination therapy. J Allergy Clin Immunol. 2013;132:101-

16. Vestergaard C, Toubi E, Maurer M, Triggiani M, Ballmer-

Weber B, Marsland A, et al. Treatment of chronic spontaneous

urticaria with an inadequate response to H1-antihistamines:

an expert opinion. Eur J Dermatol. 2017;27:10-9.

17. Kulthanan K, Chaweekulrat P, Komoltri C, Hunnangkul

S, Tuchinda P, Chularojanamontri L, et al. Cyclosporine

for Chronic Spontaneous Urticaria: A Meta-Analysis and

Systematic Review. J Allergy Clin Immunol Pract. 2018;6:586-

99.

18. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of

action that contribute to efficacy of omalizumab in chronic

spontaneous urticaria. Allergy. 2017;72:519-33.

19. Serrano-Candelas E, Martínez-Aranguren R, Valero A, Bartra

J, Gastaminza G, Goikoetxea MJ, et al. Comparable actions

of omalizumab on mast cells and basophils. Clin Exp Allergy.

2016;46:92-102.

20. Bernstein JA, Kavati A, Tharp MD, Ortiz B, MacDonald

K, Denhaerynck K, et al. Effectiveness of omalizumab in

adolescent and adult patients with chronic idiopathic/

spontaneous urticaria: a systematic review of 'real-world'

evidence. Expert Opin Biol Ther. 2018;18:425-48.

21. Sussman G, Hébert J, Barron C, Bian J, Caron-Guay RM,

Laflamme S, et al. Real-life experiences with omalizumab

for the treatment of chronic urticaria. Ann Allergy Asthma

Immunol. 2014;112:170-4.

22. Giménez-Arnau AM. Omalizumab for treating chronic

spontaneous urticaria: an expert review on efficacy and safety.

Expert Opin Biol Ther. 2017;17:375-85.

23. Asero R, Canonica GW, Cristaudo A, Fierro MT, Girolomoni G,

Marzano AV, et al. Critical appraisal of the unmet needs in the

treatment of chronic spontaneous urticaria with omalizumab:

an Italian perspective. Curr Opin Allergy Clin Immunol.

2017;17:453-9.

24. Balañá M, Valero A, Giménez Arnau A, Ferrer M, Jáuregui I,

Ballesteros C.Validation of The Spanish Version of The Urticaria

Activity Score (UAS) and Its Use Over One Week (UAS7). Value

Health. 2015;18:A426.

25. Młynek A, Zalewska-Janowska A, Martus P, Staubach P,

Zuberbier T, Maurer M. How to assess disease activity in

patients with chronic urticaria? Allergy. 2008;63:777-80.